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Medulloblastoma (MB) is the most common malignant brain tumor in children. Current 
treatment for MB, consisting of surgery followed by irradiation of the whole neuraxis and 
high-dose multi-agent chemotherapy, is only partially effective and is associated with 
highly invalidating side effects. Therefore, the identification and validation of novel target 
molecules, capable of contrasting MB growth without disturbing brain development, is 
needed. Citron kinase protein (CITK), encoded by primary microcephaly gene MCPH17, is 
required for normal proliferation and survival of neural progenitors. Constitutive loss of 
CITK leads to cytokinesis failure, chromosome instability and apoptosis in developing 
brain, but has limited effects on other tissues. On this basis, we hypothesized that CITK 
could be an effective target for MB treatment. We tested this hypothesis using the MB cell 
lines DAOY and ONS-76. In these cells, CITK knockdown increases both cytokinesis 
failure and DNA damage, impairing proliferation and inducing cell senescence and 
apoptosis via TP53 or TP73. Similar effects were obtained in MB arising in the NeuroD-
SmoA1 transgenic mouse model, in which CITK deletion increases apoptotic cells and 
senescence markers, such as P21CIP1, P27KIP1 and P16INK4A. Most importantly, CITK 
deletion decreases tumor growth and increases overall survival in these mice, with no 





Medulloblastoma (MB) is the most common malignant brain tumor in children (1). MB has 
been classified into five subgroups based on histology and into four biological subgroups 
based on microarray and genomic sequencing technologies: WNT, Sonic Hedgehog 
(SHH), group 3 and group 4 (2–6). WNT MB are associated with relatively good prognosis, 
while group 3 and 4, which often show MYC amplification and TP53 mutation, are the most 
aggressive subtypes (5). Current treatments for MB include surgery followed by irradiation 
of the whole neuraxis and high-dose multi-agent chemotherapy (7). 5-years survival rate 
for children with average and high-risk disease, as defined by clinical criteria, is 80% and 
60–65%, respectively (8). Therefore, many of the high-risk patients die despite treatment 
(9). In addition, survivors have significant neurologic and developmental consequences, 
such as severe cognitive deficits and endocrine disorders (10–15). Thus, novel and more 
specific therapies are urgently needed. A possible strategy to develop new selective 
therapies is to directly target molecular pathways altered by driver mutations. SHH 
subgroup, representing approximately 25% of MB cases, is the better understood MB 
subtype: it is characterized by mutations of SHH signaling pathway downstream 
components (PTCH1, SMO, SUFU and GLI2) and it is derived from granule neuron 
precursors (GNPs) of the cerebellum (16–18). Small-molecule inhibitors of the SHH 
pathway have been developed and tested in clinical trials (19). However, only a subgroup 
of these patients respond to treatment and even in these cases resistance rapidly 
develops (20–22). An alternative strategy for drug development is to target molecules that, 
despite not being mutated in cancer, are nevertheless required for tumor growth and 
progression (23). Cancer cells may become specifically dependent on particular non-
mutant proteins in consequence of peculiar features of the cells from which they originate 
and/or of the modifications induced by oncogenic transformation (23).  
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CITK is a conserved multi-domain protein, containing an AGC-type amino-terminal 
serine/threonine kinase domain (24,25). CITK is ubiquitously expressed (26) and cell-cycle 
regulated, with highest levels in G2/M phase of the cell cycle (27). During mitosis, it is first 
localized to the nucleus (27), it is enriched at spindle poles before anaphase (28), it is 
concentrated at cleavage furrow and midbody from anaphase to cytokinesis (25). CITK is 
a specific regulator of abscission at the end of cytokinesis (25,29–32). In addition, it 
regulates mitotic spindle orientation (33) and it is involved in genomic stability 
independently of its role in cytokinesis (34). Despite ubiquitous expression, CITK is 
functionally required in vivo only in few cell types, such as neural progenitors (26,35) and 
male germ cells (36). CITK loss leads to severe microcephaly in rodents (26,37) and 
humans (38–41). Cells in the affected tissues display cytokinesis failure (26,40), apoptosis 
(26,36,40) and accumulation of DNA damage (34). Notably, the human CITK microcephaly 
syndrome, known as MCPH17, can be caused by homozygous kinase-inactivating 
mutations (40), indicating that catalytic activity is essential for function. 
CITK is expressed at high levels in tumors (42–44) and is required for normal growth in 
tumor cell lines of different origin (45–47). Moreover, CITK knock-down reduces tumor 
growth in hepatocellular carcinoma cells in xenograft assays (45). These results suggest 
that CITK could be an interesting target for anti-cancer drug development. However, the 
effects of CITK inactivation have never been tested in primary tumors. Based on current 
knowledge (30,48), SHH MB appears to be an ideal tumor type for testing the potential of 
CITK as a candidate drug target. Indeed, cerebellar GNPs, from which SHH MB develops 
(16–18), are among the neural progenitors showing highest sensitivity to CITK loss (26). 
Moreover, MB express high levels of TUBB3 (49), which may increase sensitivity to CITK 
loss (50). Finally, while CITK is essential for normal brain development, it is not required in 
normal postnatal tissues (26,34), and therefore its acute inactivation should be associated 
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with relatively mild side effects.  
In this report we analyzed the effects of deleting CITK in SHH MB, using in vitro and in 
vivo models, including conditional inactivation in primary tumors. Our results support CITK 
as a novel drug target for this tumor type. 
 
Materials and methods 
Cell culture. 
DAOY cells were obtained from ATCC and were cultured according to the ATCC protocol.  
ONS-76 cells were kindly provided by Luigi Varesio (Gaslini Hospital, Genova) and were 
cultured in RPMI medium supplemented with 10% fetal bovine serum (FBS) and 1% 
penicillin/streptomycin (Life Technologies, ThermoFisher, Waltham, MA). For both cell 
lines, the number of in vitro passages from thawing of the original aliquots to experiments 
was comprised between 5 and 8. Cells were routinely analyzed for morphological features 
and tested for Mycoplasma contamination with the following oligonucleotides sequences: 
MYCO1 5'-ACTCCTACGGGAGGCAGCAGTA-3'; MYCO2: 5'-
TGCACCATCTGTCACTCTGTTAACCTC-3'. 
Transfection and RNAi. 
Previously published CITK double-stranded RNAs (31) and non-targeting siRNA were 
used (Dharmacon, Lafayette, CO). For knockdown of TP53 and TP73 ONTARGETplus 
Dharmacon SMART pools were used. D-001810-10 non-targeting pool was used as a 
negative control. ONS-76 and DAOY cells plated on six-well plates were transfected using 
6.25 μl of the required siRNA (20 μM) together with 1.5 μl Lipofectamine 2000 (Invitrogen, 
Carlsbad, CA), according to the manufacturer's instructions. Efficient knockdown was 




HEK293T cells were cultured in DMEM supplemented with 10% fetal Calf serum (FCS) 
and 1% penicillin/streptomycin (Life Technologies, ThermoFisher, Waltham, MA). Lentiviral 
vector stocks were produced in HEK293T cells by calcium phosphate-mediated 
transfection as described in (51). 
Generation of inducible shRNA cell lines and rescue of CITK expression. 
Human CITK-specific shRNA sequences (31) were cloned into pLVTHM vector from Didier 
Trono's lab (Addgene plasmid #12247, Fig. S1A). For inducible RNAi, cells were 
transduced with pLV-DsRed-tTRKRAB from Didier Trono lab (Addgene plasmid #12247, 
Fig. S1A), expanded, and used for transduction with pLVTH-GFP-shRNA lentiviral 
particles. Next, cells were treated with doxycycline (2 µM) for 12 hours; double 
GFP+DsRed+ cells were sorted by FACSAria (BD biosciences, Franklin Lakes, NJ) and 
expanded. Cells expressing GFP in the absence of doxycycline were considered “leaky” 
and removed by a second flow of cytometry sorting. Purified inducible cells showed 
efficient knockdown after 24h, as determined by western blot analysis. For rescue 
experiments, Myc-cherry-tagged CITK over-expression constructs encoding kinase-active 
or kinase-inactive (S222A) proteins previously described (31) were transfected at the 
same time of doxycycline induction with 10.5 µl of Lipofectamine 2000 (ThermoFisher, 
Invitrogen, Carlsbad, CA), according to the manufacturer's instructions. Live cells, as 
assessed by methylene blue staining, were counted after 24h.  
Analysis of cell death and proliferation. 
For apoptosis detection, 5 × 105 cells were collected, centrifuged at 2,000 rpm for 5 min, 
and re-suspended in 300 μl of binding buffer. Annexin V FITC (3 μl) was added and mixed. 
After the addition of 5 μl of propidium iodide (PI) staining solution, the cells were incubated 
for 15-30 min in the dark at room temperature and analyzed by flow cytometry to detect 
cell apoptosis. For cell proliferation analysis, 5x103 ONS-76 and DAOY inducible cells 
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were seeded into twenty-four-well plates and activated using doxycycline (2 µM). Live cells 
were counted in replica wells each day for six days. 
Experimental Animal Work. 
Experiments involving samples from mutant and control mice have been performed 
conforming to the Italian laws on animal experimentation, under permission number 
343/2015-PR, released on 08/05/2015 from Italian Ministry of Health, Department of Public 
Veterinary Health. Adherence to internationally accepted animal well-being standards was 
further supervised by the veterinary service of the Molecular Biotechnology Centre animal 
facility.  
Xenograft assays. 
Subcutaneous MB xenografts were obtained by transplanting in mice DAOY cells 
expressing control or CITK-targeted shRNAs under doxycycline-inducible control. Four to 
eight-week old female NOD-SCID mice (Jackson Laboratory) were injected in the flank 
with 2x106 cells. After 6 weeks, doxycycline (10 mg/ml) was added to drinking water for 
other 4 weeks. Xenograft tumors were measured every week and tumor volume was 
estimated as 4π r3 / 3. 
Mouse strains. 
The mouse strain containing the 'knockout first' allele of CitK Cittm1a(KOMP)Wtsi , in a C57BL/6 
background, was obtained from UC Davis KOMP repository. The Citron kinase conditional 
knockout allele Citflox was obtained by crossing Cittm1a(KOMP)Wtsi mice with the FLP-balancer 
line Gt(ROSA)26Sortm2(FLP*)Sor , in a C57BL/6J congenic background (The Jackson 
Laboratory, Bar Harbor, Main). The mouse strains Gt(ROSA)26Sortm1(cre/ERT2)Tyj 
(ubiquitously-expressing tamoxifen-inducible ERT2-CRE) and ND2:SmoA1 (expressing the 
constitutively active point mutant SmoA1 under the Neurod2 promoter in cerebellar 
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granule cells), both in congenic C57BL/6 background, were obtained from The Jackson 
Laboratory.  
Antibodies  
The following antibodies were used: mouse monoclonal anti-Citron (#611377 Transduction 
Laboratories, BD Biosciences, San Jose, CA, USA), mouse monoclonal anti-Vinculin 
(#V9131 Sigma-Aldrich); rabbit polyclonal anti-γH2AX (S139) (20E3) (#2577 Cell Signaling 
Technology, Danvers, MA, USA), mouse monoclonal anti-P27 (#610242 Transduction 
Laboratories, BD Biosciences, San Jose, CA, USA), rabbit polyclonal anti-cleaved 
Caspase 3 (#9661S Cell Signaling Technology, Danvers, MA, USA), goat polyclonal anti-
cleaved Caspase7 (#sc-6138 Santacruz, Dallas, TX, USA), rabbit polyclonal anti-P21 (#sc-
756 Santacruz, Dallas, TX, USA), rabbit polyclonal anti-P16 (#sc-1207 Santacruz, Dallas, 
TX, USA), mouse monoclonal anti-Ki67 (#ab15580 Abcam, Cambridge, GB), rabbit 
polyclonal anti-TP53(#sc-6243 Santacruz, Dallas, TX, USA), rabbit polyclonal anti-TP73 
(#ab14430 Abcam, Cambridge, GB), mouse monoclonal anti-αTubulin (#T5168 Sigma-
Aldrich, Saint Louis, MS, USA), rabbit polyclonal anti-βactin (#A2066 Sigma-Aldrich). 
Western blotting 
Cell lines and tissues were lysed in RIPA buffer (1% NP40, 150 mM NaCl, 50 mM TRIS 
HCl pH 8.5 mM EDTA, 0.01% SDS, 0.005% Sodium deoxycholate, Roche protease 
inhibitors, PMSF) for 10 min at 4°C. Mouse tissues were previously homogenized with T 
25 digital ULTRA-TURRAX®. Samples were clarified 10 min at 13000 rpm at 4°C. For 
immunoblots, equal amounts of proteins from both whole-cell lysates were resolved by 
SDS–PAGE and blotted to nitrocellulose membranes.  
Immunofluorescence. 
Cultured cells were fixed 5 min at RT using PFA 2% then treated 10 min at RT using CSK 
buffer [100 mM NaCl, 300 mM sucrose, 3 mM MgCl2, 10 mM PIPES (pH 6.8)], 0.7% 
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Triton, and finally fixed again 5 min at RT using PFA 2%. Mice were anaesthetized by 
using a mixture of Rompun/Zoletil and trans-cardially perfused with fixative solution (4% 
paraformaldehyde in PBS). Tumors were post-fixed overnight at 4°C, slowly dehydrated 
with increasing concentrations of Sucrose, embedded with Tissue-TEK (O.C.T, Sakura 
Finetek, Alphen aan den Rijn, The Netherlands), and frozen by using isopentane. 20μm 
cryo-sections were rehydrated in PBS before further processing. Cells and sections were 
permeabilized in 0.1% Triton X 100 in PBS for 10 min, saturated in 5% BSA in PBS for 30 
min and incubated with a primary antibody for 1h at RT. Primary antibodies were detected 
with anti-rabbit Alexa Fluor 488 or 568 (Molecular Probes, Invitrogen), anti-mouse Alexa 
Fluor 488 or 568 (Molecular Probes, Invitrogen) used at 1:500 dilution for 30 min. Cells 
were counterstained with 0.5 μg/mL DAPI for 10 min and washed with PBS. TUNEL assay 
was performed 48h post transfection using the TMR red In Situ Cell Death Detection Kit 
(Roche, West Sussex, UK), according to manufacturer protocol. Images were acquired 
using an ApoTome system (Zeiss, Oberkochen, Germany) or using a Leica TCS SP5 
confocal system (Leica Microsystems) equipped with a 405‐nm diode, an argon ion, and a 
561‐nm DPSS laser. 
Detection of senescent cells. 
Senescent cells in cultures or in xenograft tumors were detected using in situ β-
galactosidase staining, following the protocol reported described in (52)  
Immunohistochemistry 
Periodate-lysine-paraformaldehyde (PLP)-fixed and paraffin-embedded tissue sections 
were stained with haematoxylin & eosin (H&E). For immunohistochemistry assays, de-
waxed 5 µm sections were submitted to wet heat-induced antigen retrieval in a mixture of 
0.1M Tris and 0.01M EDTA solution at pH 9.0. Endogenous peroxidase was blocked in 
0.6% hydrogen peroxide solution in 0.05M TBS (pH 7.6) for 20 min at room temperature. 
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Sections were then treated with 5% normal goat serum and reacted overnight with 
antibodies. Subsequently, sections were incubated with goat anti-rabbit (ab97051; Abcam) 
or anti-mouse (ab97240; Abcam) IgG conjugated to HRP for 1h at room temperature. 
Finally, sections were treated with diaminobenzidine enhanced liquid substrate chromogen 
system (D3939; Sigma-Aldrich) and counterstained with haematoxylin. Apoptosis was 
assessed using In Situ Cell Death Detection Kit POD (Roche) according to manufacturer's 
instructions. 
Tamoxifen treatment 
In all in vivo experiments, littermate mice, homozygous for the Citflox allele, homozygous 
for the ND2:SmoA1 and possessing (iCRE+) or non-possessing (iCRE-) the ERT2 allele 
were treated for five days with 0.100mg/g of tamoxifen by intraperitoneal injection. 
Survival analysis 
Kaplan–Meier method was used to estimate survival. For tamoxifen-treated mice, two 
months-old littermates, divided in iCRE+ and iCRE- cohorts, were treated and monitored 
for health status and movement abnormalities. All mice were euthanized at the onset of 
symptoms, including 10% weight loss, ataxia, or lethargy.  
To analyze human MB patients survival in function of CITK expression, raw data of Gene 
Expression Omnibus (GEO) dataset GSE85217 (33), generated on Affymetrix Human 
Gene 1.1 ST Array platform, were downloaded and normalized through RMA algorithm as 
in Bioconductor oligo package (53). Mapping of Affy IDs to transcripts was based on 
NetAffx annotation (release na36, hg19). To specifically focus the analysis on CITK and 
exclude CITN isoform expression, we selected kinase domain probe-sets (7966920, 
7966921, 7966922, 7966923, 7966924, 7966925, 7966926, 7966927) and averaged the 
corresponding expression values in each sample. Overall Survival data were obtained 
from (33) and maximal survival time was cut at 15 years. Patients were divided in two 
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groups using median expression as the discriminant value. In both cases, statistical 
significance was set to p=0.05. Log-rank (Mantel-Cox) test was used to compare survival 
between experimental groups. 
Magnetic Resonance Imaging (MRI) 
Magnetic Resonance images were acquired at 7.1 T using a Bruker Avance 300 
spectrometer. The animals were scanned weekly, starting from 8 weeks of age, in order to 
check the presence of tumors through T2-weighted (T2w) images acquired with the 
following parameters: Repetition Time (TR) = 4000 ms; Echo Time (TE) = 59 ms; Rare 
Factor (RF) = 24; slice thickness = 1 mm; 15 slices; field of view = 3.00 cm; matrix = 256 × 
256; number of averages (NAV) = 4; total imaging time = 2m40s). Animals bearing a tumor 
mass (size 5 to 20mm3) were then imaged with a high resolution Turbo-Rare sequence 
(TR = 2500 ms, TE = 36 ms, RF = 8, slice thickness = 0.5 mm; 20 slices; field of 
view = 3.50 cm; matrix = 384 × 384; NAV = 10; total imaging time = 20 min) before and 
7,14, 21, 28 days after tamoxifen administration, to monitor tumor progression. Before 
undergoing MRI animals were anesthetized by intramuscular injection of 5 mg/kg of 
xylazine (Rompun; Bayer, Milan, Italy) and 20 mg/kg of tiletamine/zolazepam (Zoletil 100; 
Virbac, Milan, Italy). Tumor volume was assessed in each animal through MR data 
analysis, carried out with Bruker Paravision 5.1 Software. More in details, the tumor area 
was delineated in each slice of T2w high resolution images by manually drawing regions of 
interest along tumor borders. The tumor volume in each slice was estimated multiplying 
each tumor area for the slice thickness (0.5 mm). Finally, the total tumor volume was 
estimated by adding up all the single slice volumes. 
Statistical analysis  
Statistical analyses were performed using Microsoft Office Excel or Graphpad. Unpaired 
two-tails Student's t‐test was used if not otherwise specified. The mean values shown 
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represent the average of at least three independent experiments and error bars are 
standard errors of the mean. 
 
Results 
SHH medulloblastoma cells are sensitive to CITK knock-down. 
To investigate the dependence of SHH MB on CITK expression, we resorted to DAOY and 
ONS-76 cells, two established human MB lines showing a transcription profile typical of 
SHH activation (1), and carrying mutated or wild type TP53, respectively (54). We induced 
transient CITK knock-down in these cells (Fig. 1A) using two validated siRNA sequences 
(31) and analyzed CITK associated cellular phenotypes 48 hours after transfection. CITK 
loss induced apoptosis in both cell lines, as shown by high levels of cleaved Caspase-3 
and Caspase-7 (Fig. 1A-B), as well as by increased rate of annexin V-positive cells (Fig. 
1C) and of TUNEL-positive cells (Fig. 1D). In addition, after CITK knock down, both lines 
showed increased rate of binucleated cells, indicative of cytokinesis failure (Fig. 1E and 
(34)). We previously demonstrated that RNAi of CITK in ONS-76 cells leads to 
accumulation of DNA double strand breaks (DSB), as shown by higher frequency of 
γH2AX- and TP53BP1-positive nuclear foci and, most importantly, by gain of chromosome 
breaks (34). Accordingly, we found that also DAOY cells have increased frequency of 
γH2AX nuclear foci after CITK knock-down (Fig. 2A). Interestingly, in both cell lines, 
transfection of the two CITK-specific siRNA sequences significantly enhanced the 
proportion of cells in G0/G1 (Fig. 2B-C). This result suggests that, besides inducing 
cytokinesis failure, CITK loss reduces the number of MB cells that progress into S-phase 
and mitosis. Consistent with this observation, CITK-interfered ONS-76 and DAOY cells 




Previous work has shown that CITK loss may elicit both TP53-dependent and TP53-
independent effects (34,46). Accordingly, TP53 knock-down reverted to a great extent the 
apoptotic phenotype resulting from CITK RNAi in ONS-76 cells but had little effect in CITK-
interfered DAOY cells (Fig. 3A-B). Since we previously showed that CITK loss increases 
TP73 RNA levels independently of the TP53 status (34), we assessed whether TP73 is 
involved in phenotypes produced by CITK loss in DAOY cells. As expected, TP73 protein 
levels are significantly increased in DAOY cells after CITK RNAi (Fig. 3C and 3D). 
Moreover, when the induction of TP73 was prevented by RNAi (Fig. 3C and 3D), apoptosis 
levels were significantly reduced (Fig. 3E) and the induction of growth arrest markers was 
not observed (Fig. 3C and 3F). Interestingly, TP53 or TP73 knock-down induced by itself a 
moderate increase of apoptosis levels. Taken together, these observations suggest that 
SHH MB cells are highly sensitive to CITK loss, which increases the frequency of DNA 
damage and cytokinesis failure and leads to apoptosis and cell cycle-progression block via 
TP53 or TP73. 
Stable CITK knock-down impairs the expansion of SHH medulloblastoma cells in 
vitro and in xenograft assays. 
To better evaluate the impact of CITK loss on SHH MB cells’ growth, we generated DAOY 
and ONS-76 cell lines conditionally expressing control and CITK-specific shRNAs. To this 
aim, we cloned previously validated CITK sequences into a tightly regulated lentiviral-
based system, in which shRNA expression can be induced by doxycycline administration 
(51) (Fig. S1A). Polyclonal populations obtained from both MB cell lines showed efficient 
CITK knockdown 48 hours after doxycycline administration (Fig. S1B). Stable knock-down 
of CITK recapitulated all the phenotypes produced by transient one (Fig. S1C-D). 
Furthermore, in long term colony forming assay, both DAOY and ONS-76 cells showed 
reduced growth rates compared to controls, after CITK shRNA induction by continuous 
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exposure to doxycycline (Fig. 4A-B). In addition, CITK knocked-down cells had a 
senescent morphology (Fig. 4C). Accordingly, CITK shRNA induction led to strong 
increase of cells positive for β-galactosidase cytochemical reaction (Fig. 4D), which is 
typical of senescent cells (52). To assess whether anti-proliferative effects of CITK loss are 
dependent on kinase activity, we used ONS-76 cells expressing CITK1 shRNA and 
performed rescue assays with overexpression vectors, coding for mouse CITK proteins. 
Interestingly, in CITK knocked down cells, transfection of RNAi-resistant wild type CITK 
(Fig. S1E) restored cell growth at control levels, while kinase-dead mutant did not revert 
the phenotype (Fig. 4E). This result indicates that CITK catalytic activity is required for 
SHH MB cells proliferation. 
Next, we investigated whether CITK might be required for SHH MB cell expansion also in 
vivo, by performing xenograft assays with shRNA-expressing cell lines. In particular, 
considering the established malignant potential of DAOY cells and the higher effectiveness 
of the CITK1 sequence, we subcutaneously injected into immunodeficient mice DAOY 
cells, transduced with inducible control or with CITK1 shRNAs-containing lentiviruses. In 
mice fed with doxycycline-free diet, palpable tumors developed within six weeks after 
injection and underwent rapid growth afterwards (Fig. 5A). Continuous doxycycline 
administration had no significant effects on growth of tumors expressing control shRNA 
(Fig. 5A). In contrast, treatment reduced significantly the growth of CITK1 shRNA-
expressing tumors (Fig. 5A-C). Interestingly, tumors expressing CITK1 shRNA showed 
also higher positivity to β-galactosidase staining, if compared to controls (Fig. 5D). Taken 
together, these results suggest that the inhibition of CITK impairs growth and induces cell 
senescence in SHH MB cells independently of TP53 status, both in vitro and in vivo.  
CITK inactivation inhibits SHH-medulloblastoma progression.  
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CITK is not frequently mutated in human cancers (46) but is overexpressed in different 
tumor types (43–45), while it is expressed at very low levels in normal brain (55,56). By re-
analyzing gene expression data of a recently published MB cohort (33), we found that 
tumors expressing CITK at levels higher than median have worse prognosis (Fig. S2A). 
We therefore asked whether CITK loss-of-function may elicit anti-neoplastic effects in 
patient-like MB. To this aim, we set out to induce CITK inactivation in tumors arising in the 
cerebellum of SmoA1 transgenic mice (57). This line expresses a constitutively active form 
of Smoothened gene (Smo) in cerebellar GNPs under the control of NeuroD2 promoter 
(57) and shows, especially when crossed to homozygosity, high incidence of MB, closely 
mimicking the human disease (58). SmoA1 MB show high expression of CITK, if 
compared to the levels observed during normal cerebellar development (Fig. S2B). To 
inactivate CITK in these tumors in a temporally-controlled manner, we developed a mouse 
conditional CitK allele, in which the third exon is flanked by LoxP sites (CitKflox, Fig. S3A). 
We then crossed this allele to homozygosity into transgenic mice constitutively expressing 
a tamoxifen-inducible ERT2CRE enzyme from Rosa26 locus (59). We assessed the 
effectiveness of conditional deletion by analyzing the ratio between recombined and non-
recombined alleles (Fig. S3B), as well as CITK protein levels (Fig. S3C), in tissues of mice 
homozygous for CitKflox (CitKflox/flox) and heterozygous for ERT2CRE, treated with tamoxifen 
at postnatal day (P)60. Recombination of the CitKflox allele was efficiently induced by 
tamoxifen in lymphoid tissues (Fig. S3B-C). No significant histological differences were 
observed in thymus and spleen of CITK-deleted and control mice (Fig. S3D). One year 
follow up of a cohort of such mice did not show significant survival differences or 
pathologic abnormalities between treated ERT2CRE - and ERT2CRE+ CitKflox/flox mice (data 
not shown). CITK deletion was not detected in mature brain (Fig. S3B), which mostly 
expresses the kinase domain-lacking isoform CITN (56) (Fig. 6A). However, since 
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effectiveness of tamoxifen-induced recombination could depend on proliferative activity or 
differentiation-related phenomena, we crossed the above mice with the SmoA1 line, to 
generate mice homozygous for SmoA1 and CitKflox alleles, and either ERT2CRE-negative 
(control, iCRE-) or ERT2CRE-positive (iCRE+). Under basal conditions, both iCRE- and 
iCRE+ mice developed MB, with similar frequency and in comparable times as SmoA1 
transgenic mice (data not shown). To evaluate whether CITK could be inactivated in these 
tumors, as well as the effects of CITK acute loss, we injected tamoxifen for 5 consecutive 
days in mice showing at MRI MB of similar size (3-20 mm3 diameter) and analyzed them 5 
days after the last injection. Western blot analysis confirmed that tamoxifen treatment is 
effective in blunting CITK expression in iCRE+ tumors, but not in iCRE- controls (Fig. 6A). 
DNA analysis confirmed the effectiveness of recombination, but also showed that a 
significant fraction of cells in the tumors did not undergo CRE-mediated deletion (Fig. 
S3E). Nevertheless, tamoxifen-treated iCRE+ tumors showed increased levels of γH2AX, 
P21, P27 and P16, as well as cleaved Caspase-3 and Caspase-7 (Fig.6A-B). These 
results confirm that CITK loss leads to increased DNA damage, apoptosis and cell 
senescence in MB. Histopathological analysis revealed striking differences in cellular 
organization between tamoxifen-treated iCRE- and iCRE+ tumors. In iCRE- tumors, cells 
showed a whorl-packed-like arrangement organization (Fig. 6C); it is interesting to note the 
high number of macrophagic cells phagocitying apoptotic cell debries giving a pattern of 
“starry sky”, as it was reported in tumors with high proliferative index like Burkitt’s 
Lymphoma (60). In contrast, the morphological structure of tamoxifen-treated iCRE+ 
tumors was more heterogeneous, characterized by areas of packed small cells interleaved 
by areas of low cellular density (Fig. 6C). Immunohistochemical analysis underlined that 
the latter cells express low levels of the proliferation marker Ki67 and high levels of P27 
(Fig. 6C). In addition, in P27-positive cells of CITK-deleted tumors, P27 was mostly 
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localized in the nucleus, as it would be expected in senescent cells (61), while in CITK-
proficient tumors it was found in the cytoplasm (Fig. 6D). Conversely, cells in dense areas 
were mostly Ki67-positive and P27-negative (Fig. 6C). Consistent with biochemical data, 
we observed increased frequency of TUNEL-positive cells in sections of iCRE+ tumors 
(Fig. 6E).  
To assess the overall anti-tumor effect of CitK deletion, we monitored tumor growth by 
MRI, before and after tamoxifen administration. This analysis showed that CITK loss 
impairs MB growth during the first four weeks after treatment (Fig. 7 A-B). In the end, we 
evaluated whether CitK deletion may significantly affect the survival of SmoA1 mice. To 
this aim, we treated with tamoxifen two months-old iCRE- and iCRE+ mice. At this stage 
more than 90% of SmoA1 homozygous mice are expected to develop sub-clinical tumors 
(58). Kaplan-Meier curves showed a significant increase in survival of the iCRE+ mice 
(Fig. 7C). Interestingly, western blot analysis of advanced tumors isolated from both 
groups revealed that all of them expressed similar levels of CITK, while the spleen of 
iCRE+ was still CITK-deficient (Fig. 7D). 
Altogether, these results indicate that CITK deletion inhibits SmoA1 MB progression. 
 
Discussion 
In this report we explored the potential suitability of CITK as a target for MB therapy, by 
producing transient or stable RNAi-mediated knockdown in human MB cell lines, as well 
as temporally-controlled genetic inactivation in mouse MB of SmoA1 transgenic model. 
Data obtained in human MB cells confirmed that CITK is necessary for their in vitro 
expansion and that CITK loss leads to high frequency of cytokinesis failure and apoptosis, 
similarly to what has previously been described in developing neural progenitors (26,40) 
and in non-neural tumor cell lines (31,45,46,62). We also confirmed that DNA damage is a 
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prominent consequence of CITK loss (34). Interestingly, the strongest effect produced by 
CITK knock-down on cell cycle profile, was an increase in the proportion of G0/G1 cells, 
suggestive of high frequency of cell cycle arrest. This finding was partially unexpected, 
since previous studies in tumor cell lines (46,62) and in CitK knockout mice (26) reported 
an increase of G2/M or binucleated cells as the main alteration, correlating with high 
frequency of cytokinesis failure. Considering the change of cell morphology, as well as the 
increased positivity for β-galactosidase and the strong induction of cyclin kinase inhibitors 
P21 and P27, we conclude that human MB cell lines respond to CITK loss mainly by 
undergoing growth arrest and senescence, although cytokinesis failure is also detectable. 
A combination of apoptosis and senescence may therefore be responsible for the reduced 
expansion of cells after CITK knock-down, both in culture and in xenograft assays.  
Interestingly, we observed a similar response in TP53-proficient ONS-76 cells and in 
DAOY cells, expressing non-functional TP53, supporting the notion that CITK loss may 
lead to both TP53 dependent and TP53 independent anti-proliferative responses (34,46). 
Functional studies (Fig. 3) confirmed that wild type TP53 is a crucial player of the 
phenotypes elicited by CITK loss, and suggest that its role may be at least partially 
compensated by TP73. It is worth noting that TP53 knock-down in DAOY cells and both 
TP53 or TP73 knock-down in ONS-76 cells moderately increased per se apoptosis levels. 
In the first case, the phenomenon could be justified by the oncogenic activity of a mutant 
TP53, as previously reported in other cancer cell lines (63). A possible explanation of the 
ONS-76 results could be instead that wild type TP53 or TP73 knock-down may increase 
apoptosis in these cells by increasing the frequency of catastrophic mitoses. However, 
more detailed studies are necessary to better understand this phenomenon.   
Analysis of a large gene expression dataset of MB patients’ revealed that CITK expression 
is associated with worse prognosis (Supplementary Fig. S2A), but we cannot exclude that 
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this correlation may indirectly depend on mitotic activity, since CITK expression is cell 
cycle-dependent (27). 
To analyze the effects of CITK inactivation in tumors mimicking patients’ MB, we resorted 
to the SmoA1 transgenic model (57), in which we engineered temporally-controlled CitK 
deletion. With regard to these experiments, it must be underscored that tamoxifen-induced 
CitK deletion was only partially effective, although it acutely abolished CITK expression. 
Nevertheless, after tamoxifen treatment, CITK-deleted tumors showed increased 
apoptosis, as well as morphological, immunohistochemical and biochemical changes 
highly suggestive of senescence induction. Accordingly, CITK-deleted tumors showed 
reduced growth rate. Moreover, and most importantly, mice in which CITK was deleted at 
a pre-clinical stage had significantly improved survival, compared to non-deleted 
littermates similarly treated with tamoxifen. At the end of the follow-up period, tumors that 
developed in tamoxifen-treated iCRE+ mice showed CITK protein levels similar to those of 
iCRE- tumors, further indicating that CITK-deleted MB cells have a selective disadvantage 
if compared to non-deleted cells. These results indicate that deletion of CitK may favorably 
affect the clinical outcome of primary SHH-MB. It will be interesting to test whether similar 
effects can be produced by inactivating CITK in models of type III and type IV MB. In 
addition, it will be important to assess whether combination of CITK inactivation and 
established anti-MB treatments could act synergistically to increase tumor cells' death. 
Reduced growth rate of MB cells expressing shRNAs against CITK could be rescued by 
expression of wild type CITK, but not by the corresponding kinase-defective mutant, 
suggesting that CITK catalytic activity is permissive for MB growth. Little is known about 
the CITK substrates that may be important for this activity. Myosin light chain, initially 
proposed as potential substrate, was not supported by in vivo evidence (64). Presently, the 
only bona-fide CITK substrate is the mitotic protein INCENP (65) but it is unknown whether 
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CITK-dependent INCENP phosphorylation may affect genomic stability. CITK is capable of 
interacting with different proteins linked to the accumulation of DNA damage such as P27 
(66), ASPM (28), CK2α (50) and RAD51 (34), but it is still unknown whether some of these 
partners are direct substrates.  
Nevertheless, based on the present results, as well as on finding that microcephaly 
patients with homozygous CITK null mutations or kinase-inactivating mutations show 
overlapping clinical phenotypes (40), we expect that CITK specific inhibitors should induce 
in MB biological responses resembling those produced by CITK loss of function. The 
development of such molecules will therefore represent a crucial topic for future research.  
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Figures legends  
Figure 1. CITK knockdown leads to apoptosis and cytokinesis failure in 
medulloblastoma cell lines. 
(A) Western blot of total cell lysates obtained from DAOY and ONS-76 cells, treated for 48 
hours with non-targeting (siCtrl) or CITK-specific (siCITK1, siCITK2) siRNA sequences. 
Levels of CITK and of cleaved forms of Caspase 3 (cC3) and 7 (cC7) were analyzed. 
Internal loading control was Vinculin (VINC).  
(B) Quantification of the relative density of cC3 and cC7 in siCITK1 cells, compared to 
cells treated with siCtrl. (N=5). 
(C) Quantification of annexin V positive DAOY and ONS-76 cells, 48h after transfection 
with siCtrl or with two different CITK-specific siRNA sequences (N=15). 
(D) DAOY and ONS-76 cells were treated for 48 hours with siCtrl or siCITK1 and apoptotic 
cells were quantified. On the left, representative images of DAOY and ONS-76 analyzed 
with TUNEL (in red) and counterstained with DAPI. On the right, quantification of TUNEL 
positive cells.  
(E) DAOY cells, seeded at low density, were processed for immunofluorescence 48h after 
transfection with non-targeting or CITK-specific siRNA sequences, and stained with DAPI 
and anti-alpha-tubulin antibodies. The percentage of binucleated cells was then assessed.  
All quantifications were based on three independent biological replicates, unless noted 
otherwise. Error bars = standard error of the mean. * P < 0.05, ** P < 0.01, *** P < 0.001, 
two tailed Student’s T-test. Scale bars = 20 µm 
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Figure 2. Medulloblastoma cell lines accumulate DNA damage and arrest their cell 
cycle after CITK knock down.  
(A) High magnification of DAOY cells treated treated for 48 hours with siCtrl or siCITK1, 
stained with the DNA-damage marker γH2AX and counterstained with DAPI. On the right, 
quantification of γH2AX foci per nucleus. 
(B) Flow-cytometric analysis of DNA content in DAOY and ONS-76 cells, treated as in 
panel A. 
(C) Quantification of diploid (G0-G1), S-phase and tetraploid (G2-M) cells distribution in 
experiments performed as in panel B. All the differences between CITK-specific siRNAs 
and controls were significant (p < 10-7, Chi-square test performed assuming the null 
hypothesis that cell cycle distribution is independent on siRNAs condition). 
(D) Western blot of total cell lysates obtained from DAOY and ONS-76 cells, treated as in 
panel A. Levels of P27 and P21 were analyzed. Internal loading control was Vinculin 
(VINC).  
(E) Quantification of the relative intensity of P27 and P21 in western blot analysis 
performed as in panel D. 
All quantifications were based on four independent biological replicates. 
Error bars = standard error of the mean. * P < 0.05, ** P < 0.01, *** P < 0.001 (Mann-
Withney U test for panel A, two tailed Student's T-test for blots). Scale bars = 20 µm 
Figure 3. CITK loss in medulloblastoma cells induces TP53-dependent and TP53-
independent response. 
(A) Western blot of total cell lysates obtained from DAOY and ONS-76 cells, treated for 48 
hours with the indicated siRNA sequences (+). Samples in which a specific targeting 
sequence was missing (-) were treated with same amount of non-targeting control 
sequence. Internal loading control was Vinculin (VINC).  
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(B) Quantification of annexin V positive DAOY and ONS-76 cells, 48h after transfection 
with the indicated siRNA sequences (N=at least to 8). 
(C) Western blot of total cell lysates obtained from DAOY cells, treated for 48 hours with 
the indicated siRNA sequences. 
(D) Quantification of the relative intensity of TP73 in western blot analyses performed as in 
panel C (N=4). 
(E) Quantification of annexin V positive DAOY, 48h after transfection with the indicated 
siRNA sequences (N=at least 7). 
(F) Quantification of the relative intensity of P27 and P21 in western blot analyses 
performed as in panel C (N=4). 
Error bars = standard error of the mean. * P < 0.05, ** P < 0.01, *** P < 0.001, two tailed 
Student’s T-test. 
Figure 4. CITK loss decreases proliferation and induces senescence in 
medulloblastoma cell lines. 
(A) DAOY and ONS-76 cells, stably transfected with inducible non targeting (shCtrl) or 
CITK-specific shRNA sequences (CITK1 and CITK2), were plated (5000 cells) in control 
medium (Vehicle) or in Doxycycline-containing (Doxy) medium (2 μM). Growth curves 
were then obtained by assessing cell number in dishes at the indicated times. 
(B) DAOY and ONS-76 cells, expressing non targeting or CITK-specific shRNA sequences 
under Doxycycline-inducible control, were plated in 35 mm dishes (500cells/dish) 48 hours 
after shRNA induction with 2 µM Doxycycline. After additional 5 days of continuous 
exposure to Doxycycline, the obtained colonies were fixed and stained with crystal violet.  
(C) Phase contrast images of representative fields, in cultures of DAOY and ONS-76 cells, 
expressing shCtrl or shCITK1, 5 days after doxycycline induction. 
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(D) Quantification of the percentage of β-Galactosidase positive colonies in cultures 
treated as in B, five days after doxycycline administration. 
(E) ONS-76 cells, obtained as in B, were induced with doxycycline for 24 hours and then 
transfected with control vector (OE Myc) or with vectors over expressing mouse wild type 
(OE CitK) or Citron kinase inactive form (OE CitKd). Cell number in dishes was then 
quantified 24 hours later. 
All quantifications were based on five independent biological replicates. Error bars = 
standard error of the mean. * P < 0.05, ** P < 0.01, *** P < 0.001, n.s. = non-significant, 
two tailed Student's T-test. Scale bars = 20 µm 
Figure 5. CITK knock down decreases growth and induces senescence in DAOY 
xenograft tumors. 
(A) DAOY cells stably transduced with the indicated shRNA vectors were injected 
subcutaneously in NOD-SCID mice. Tumor growth was monitored weekly. Doxycycline 
(Doxy) 10mg/ml or ethanol (Vehicle) was added to the drinking water six weeks after cells 
injection, and tumor growth was monitored for three additional weeks. 
 Analysis of xenograft tumors growth was performed by measuring subcutaneous tumor 
diameter.  
(B) Quantification of tumor weight after explantation, performed at the end of the 
experiments described in A. 
(C) Representative pictures of xenograft tumors, obtained after explantation at the end of 
the experiments described in A. 
(D) Representative pictures of xenograft tumors obtained from doxycycline-treated mice 
and stained with β-galactosidase assay.  
33 
 
All quantifications were based on seven independent biological replicates. Error bars = 
standard error of the mean. * P < 0.05, ** P < 0.01, two tailed Student's T-test. Scale bars 
= 50 mm. 
Figure 6. Loss of CITK leads to senescence and apoptosis in primary 
medulloblastoma. 
(A) Western blot analysis, performed with indicated antibodies, of total cell lysates 
obtained from MB explanted from mice homozygous for SmoA1 transgene and for 
conditional CitKflox allele, and either negative (iCRE-) or positive (iCRE+) for ERT2Cre 
allele, whose activity was induced by tamoxifen treatment (5 days 0.100mg/g). Explants 
were obtained 5 days after the last tamoxifen injection. Results of two independent tumors 
per each genotypes are shown. cC3 and cC7 represent cleaved Caspase 3 and 7, 
respectively. Internal loading control was Vinculin (VINC). Note that the anti-CIT antibodies 
recognize both CITK and CITN isoforms. 
(B) Quantification of the ratio between signals obtained in iCRE+ and iCRE- mice, in 
experiments performed as described in A.  
(C) Paraffin sections from tumors obtained as in panel A were analyzed by histology using 
H&E staining, as well as by immunohistochemistry with antibodies anti Ki67 and P27 
antigens. Immunohistochemistry samples were counterstained with hematoxylin. 
(D) Frozen sections of MB obtained as in A were processed for immunofluorescence, 
stained using anti P27 antibodies and counterstained with DAPI. Note the nuclear 
accumulation of P27 in iCRE+ tumors.  
(E) TUNEL staining (brown nuclei) of paraffin sections obtained as in panel A, 
counterstained with hematoxylin and quantification of TUNEL positive cells. 
All western blot quantifications were based on five independent biological replicates. 
Immunohistochemistry analysis and TUNEL quantification based on three independent 
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biological replicates. Error bars = standard error of the mean. * P < 0.05, ** P < 0.01, *** P 
< 0.001, two tailed Student's T-test. Scale bars = 30 µm. 
Figure 7. CitK deletion reduces MBs progression and increases SmoA mice 
survival. 
(A) Representative T2 weighted MRI-based follow up of MB originating in iCRE- or iCRE+ 
mice at different time points after tamoxifen treatment (time 0). Original images in 
grayscale as well as pseudo-colorized images are displayed; red and yellow lines outline 
the tumor area in MRI sections.  
(B) Quantitative analysis of tumor growth, in follow up experiment performed as described 
in panel A. Tumor volumes were reconstructed summing up the corresponding voxels in 
each section (N=6). Error bars = standard error of the mean. * P < 0.05, ** P < 0.01, two 
tailed Student’s T-test. 
(C) Kaplan-Meier survival curves of control (iCRE-) and CITK-deleted (iCRE+) mice, 
treated for 5 days with tamoxifen at 9 weeks of age (N=at least 30). Log-rank (Mantel-Cox) 
test was used to compare survival between experimental groups. 
(D) Western blot analysis of CITK levels, in cell lysates obtained from control (iCRE-) and 
CITK-deleted (iCRE+) tumors, explanted one week or 28 weeks after the end of tamoxifen 
treatment. Internal loading control was beta actin (ACTB). 
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